background

PURAPLY® AM & PURAPLY® XT
scientific data

Discover the antimicrobial effectiveness within PuraPly®AM
and PuraPly®XT in both in vitro and in vivo nonclinical studies.

Substantial MRSA reduction without compromising WOUND HEALING CELLS1

STUDY BACKGROUND

KEY STUDY FINDINGS

Compared MRSA colonies in each
wound, using a porcine deep reticular
dermal wound model

PuraPly® AM & PuraPly® XT provided
persistent and significantly greater antimicrobial effectiveness within the products1

In vivo: Microbiology

ANTIMICROBIAL
EFFECTIVENESS WITHIN
PURAPLY AM & PURAPLY XT†

>99%

MRSA reduction from
post-debridement baseline1

In vivo: Superior MRSA reduction

MRSA counts

aP<0.05 vs pre- and post-debridement baseline; bP<0.05 vs Aquacel Ag and PriMatrix Ag; cP<0.05 vs BlastX; dP<0.05 vs pre-debridement baseline

Data shown compared MRSA colonies in each wound, using a porcine deep reticular dermal wound model
*Wounds were inoculated with MRSA and were allowed to form biofilm for 72 hours; the wounds were then debrided before the application of testing agent

† In a study evaluating the antimicrobial effectiveness within PuraPly AM and PuraPly XT versus a variety of other wound products

MRSA=methicillin-resistant Staphylococcus aureus

STUDY BACKGROUND

KEY STUDY FINDINGS

Measured cell proliferation and cell viability using human dermal fibroblasts in media conditioned with test materials

PuraPly® AM & PuraPly® XT did not prohibit cell proliferation and were non-cytotoxic to wound healing cells, unlike topical treatments1

In vitro: Cytotoxicity

PURAPLY AM & PURAPLY XT
LOW CYTOTOXICITY

>94%

Fibroblast viability
at 48 hours1

In vitro: Low cytotoxicity

Fibroblast ProliferationCell Viability
aP<0.05 vs pre- and post-debridement baseline; bP<0.05 vs Aquacel Ag and PriMatrix Ag; cP<0.05 vs BlastX; dP<0.05 vs pre-debridement baseline

Data shown compared MRSA colonies in each wound, using a porcine deep reticular dermal wound model

STUDY RESULTS

Find out more about the
published study results

DOWNLOADfile

BROAD-SPECTRUM
ANTIMICROBIAL EFFECTIVENESS

In a United States Pharmacopeia Antimicrobial Effectiveness Test, PuraPly® AM effectively reduced concentrations of the following microbes at days 7, 14, and 28 within the product2

Candida albicansEscherichia coliStaphylococcus aureus
MRSA*Aspergillus nigerPseudomonas
aeruginosa
Petri dishes
*Zone of inhibition test demonstrated efficacy in vitro.

SUPPORTING WOUND CLOSURE
IN REAL-WORLD STUDIES

See how PuraPly® AM supported healing in real-world studies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly® AM and PuraPly® XT can help your patients.

Please refer to the PuraPly AM Instructions for Use and
PuraPly XT Instructions for Use for complete prescribing information.

References:

1. Davis SC, et al. Int Wound J. 2022;19(1):86-99.2. Data on file. USP Antimicrobial Effectiveness Test. Organogenesis Inc